Paul Grayson

Paul Grayson is a Venture Partner at Versant Ventures based in the San Francisco Bay Area, where he specializes in healthcare and therapeutics investments. Before assuming his current role in 2022, he served as a Managing Director at the firm and held executive positions at major biotechnology companies including Genentech and Gilead Sciences. Throughout his venture capital career, he has supported a portfolio of over 100 companies and contributed to notable public exits, such as the 2016 initial public offering of CRISPR Therapeutics. Grayson, who holds a PhD in biochemistry from Stanford University, recently participated in venture funding rounds exceeding $100 million for early-stage biotechnology companies throughout the 2024 fiscal year. His current professional focus involves aligning early scientific research with commercialization strategies to scale emerging life sciences and healthtech enterprises across the broader healthcare sector.